Stock ENSC ENSYSCE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Market Closed - Nasdaq
Other stock markets
 21:30:01 10/05/2024 BST 		5-day change 1st Jan Change
0.524 USD -3.23% Intraday chart for Ensysce Biosciences, Inc. -6.60% -50.57%
03-21 Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
03-15 Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ENSYSCE BIOSCIENCES, INC. Stock Ensysce Biosciences, Inc.
-50.57% 3.97M -
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
A
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ENSC Stock
  4. Ratings Ensysce Biosciences, Inc.